Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Austin Daily Sun.
Press releases published on July 2, 2025
Middlesex Recovery Unveils Brand Refresh to Reflect Unified Identity with BayMark Health Services
GlobeNewswire
·
July 2, 2025
LEWISVILLE, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Middlesex Recovery, a provider of office-based opioid treatment for substance use disorders, has introduced a brand refresh that reflects its alignment with BayMark Health Services and its family of …
Cizzle Bio Announces Live Investor Webinar on Transforming Lung Cancer Detection
GlobeNewswire
·
July 2, 2025
San Antonio, TX, July 02, 2025 (GLOBE NEWSWIRE) -- Cizzle Bio today announced a live investor webinar scheduled for July 15, 2025, at 1:30 PM PST that will showcase the company’s patented blood test for early-stage lung cancer detection and the commercial …
Whitestone REIT Announces Second Quarter 2025 Earnings Webcast and Conference Call
GlobeNewswire
·
July 2, 2025
HOUSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced that it will release its financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. …
Chuck E. Cheese Teams Up with Warner Bros. Pictures for DC Studios’ SUPERMAN Movie Launch: “Fly With A Friend” Promotion Takes Off Nationwide
GlobeNewswire
·
July 2, 2025
IRVING, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Chuck E. Cheese, the world’s leading family entertainment destination, is proud to announce an exciting new partnership with Warner Bros. Pictures in support of the upcoming release of Superman, flying into …
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire
·
July 2, 2025
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the …
Own. App Partners with WallStreetBets to Build Creator-Owned Media Ecosystem; Founder Jaime Rogozinski Joins as Strategic Advisor
GlobeNewswire
·
July 2, 2025
Austin, TX, July 02, 2025 (GLOBE NEWSWIRE) -- Own. App, the next-generation social media platform built on content ownership and direct creator monetization, today announced a strategic partnership with Jaime Rogozinski, founder of WallStreetBets, to …
Solera und AkzoNobel schließen Partnerschaft zur Förderung datengestützter Nachhaltigkeit in der Fahrzeugreparatur
GlobeNewswire
·
July 2, 2025
WESTLAKE, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Solera, der weltweit führende Anbieter von Lösungen für das Management des Fahrzeuglebenszyklus, kündigte heute eine strategische Partnerschaft mit AkzoNobel Vehicle Refinishes an – einem weltweit …
Solera et AkzoNobel s’associent pour impulser le développement durable en s’appuyant sur les données dans le domaine de la réparation de véhicules
GlobeNewswire
·
July 2, 2025
WESTLAKE, Texas, 02 juill. 2025 (GLOBE NEWSWIRE) -- Solera, le leader mondial de la gestion du cycle de vie des véhicules, annonce aujourd’hui un nouveau partenariat stratégique avec AkzoNobel Vehicle Refinishes, une des entreprises internationales leader …
KBR Supports Axiom Mission 4 Launch to International Space Station with Embedded Flight Controllers and Astronaut Training
GlobeNewswire
·
July 2, 2025
HOUSTON, July 02, 2025 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) supported the successful launch and execution of Axiom Mission 4 (Ax-4), the fourth private astronaut mission to the International Space Station, marking a significant milestone in the company’s …
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
GlobeNewswire
·
July 2, 2025
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) …